Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What’s Next For Antacid/Analgesic OTCs After Negative US FDA Panel?

Executive Summary

Nonprescription Drug and the Drug Safety and Risk Management advisory committees jointly vote 15-5 that combining antacid with aspirin, acetaminophen or other analgesic ingredients is not a combination that should be allowed under an OTC monograph.


Related Content

FDA Should Call Last Round For OTC Hangover Indication, Cmte. Suggests
Recent And Upcoming FDA Advisory Committee Meetings
US FDA Serves One Antacid/Analgesic Question For AdComm, Opens Tap On Hangover Discussion
Safety Review For Upset Stomach, Hangover OTCs Reconsiders Science
OTC Antacid/Aspirin Bleeding Risk Raises Concerns At CDER


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts